Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

@article{Heerspink2019AtrasentanAR,
  title={Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial},
  author={Hiddo J Lambers Heerspink and HANS-HENRIK D. Parving and Dennis L. Andress and George Bakris and Ricardo Correa-Rotter and Fan Fan Hou and Dalane W. Kitzman and Don Kohan and Hirofumi Makino and John J.V. McMurray and Joel Z. Melnick and Michael G. Miller and Pablo E. Pergola and Vlado Perkovic and Sheldon W. Tobe and Tingting Yi and Melissa Wigderson and Dick de Zeeuw and Alicia Elbert and Augusto Vallejos and Andres Alvarisqueta and Laura Maffei and Luis Juncos and Javier de Arteaga and Gustavo C. Greloni and Eduardo dos Ramos Far{\'i}as and Alfredo Zucchini and Daniel Vogel and Ana Mar{\'i}a Cusumano and Juan Vila Santos and Margaret B. Fraenkel and Martin P. Gallagher and Tim Davis and Shamasunder Acharya and D. Cooke and Michael G. Suranyi and Simon D. Roger and Nigel D. Toussaint and Carol A. Pollock and Doris T. Chan and Stephen N. Stranks and Richard J. MacIsaac and Zoltan Endre and Alice Schmidt and Rudolf Prager and Gert Mayer and Xavier Warling and Michel Jadoul and J M Hougardy and Chris Vercammen and Bruno Van Vlem and Pieter Gillard and Adriana Forti and Jo{\~a}o Lindolfo Cunha Borges and Luis Santos Canani and Freddy Goldberg Eliaschewitz and Silmara AO Leite and Fadlo Fraige Filho and Raphael Paschoalin and Jose Andrade Moura Neto and Luciane M Deboni and Irene L. Noronha and Cintia Cercato and Carlos Alberto Prompt and Maria Teresa Zanella and Nelson Rassi and Domingos O. D'avila and Ros{\^a}ngela Milagres and Jo{\~a}o Soares Fel{\'i}cio and Roberto Pecoits Filho and Miguel Carlos Riella and Jo{\~a}o Eduardo Nunes Salles and Elizete Keitel and Sergio Ant{\^o}nio Draibe and Celso Amodeo and Joseph T. Youmbissi and Louise Roy and Serge H. Cournoyer and Shivinder Jolly and Vincent Pichette and Gihad E Nesrallah and Harpreet S. Bajaj and Hasnain M. Khandwala and Ronnie Aronson and Richard Goluch and Paul Tam and Christian G. Rabbat and Gordon Bailey and Stephen S. Chow and A. Castillo and Alfredo Danin Vargas and F Gonz{\'a}lez and Rodrigo Mu{\~n}oz and Vicente Guti{\'e}rrez and Gonzalo Godoy and Hongwen Zhao and Zhangsuo Liu and Minghui Zhao and Xiaohui Guo and Benli Su and Shu-xia Fu and Yan Xu and Jinkui Yang and Bingyin Shi and Guanqing Xiao and Wei Shi and Chuanming Hao and Changying Xing and Fanfan Hou and Qun Luo and Yuxiu Li and Linong Ji and Li Zuo and Songling Wang and Zhaohui Ni and Guohua Ding and Nan Chen and Jiajun Zhao and Weiping Jia and Sheng-qiang Yu and Jian Weng and Gang Xu and Ping Fu and Shiren Sun and Bicheng Liu and Xiaoqiang Ding and Ivan Rychl{\'i}k and Alexandra Oplustilova and Dagmar Bart{\'a}{\vs}kov{\'a} and V{\'a}clava Honov{\'a} and Hana Chmel{\'i}{\vc}kov{\'a} and Martin Petr and Petr Bucek and V. Tesar and Emil Zahumensky and Johan Vestergaard Povlsen and Kenneth Egstrup and Anna Ewa Oczachowska-Kulik and Peter Rossing and Jorma Lahtela and Jorma Strand and Ilkka Kantola and Catherine Petit and Christian Combe and Philippe Zaoui and Vincent Esnault and Pablo A Ure{\~n}a Torres and Jean-Michel Halimi and Bertrand Dussol and Tasso Bieler and Klemens Budde and Frank Dellanna and Thomas Segiet and Christine Kosch and Hans Schmidt-Guertler and Isabelle Schenkenberger and Volker Vielhauer and Frank Pistrosch and Mark Dominik Alscher and Christoph Hasslacher and Christian Hugo and Anja Muehlfeld and Christoph Wanner and Ploumis S. Passadakis and Theofanis Apostolou and Nikolaos Tentolouris and Ioannis Stefanidis and Konstantinos Mavromatidis and Vasilios Liakopoulos and Dimitrios S. Goumenos and Konstantinos Siamopoulos and Vincent T Yeung and Risa Ozaki and Samuel K Fung and Kathryn Choon-Beng Tan and Sydney Chi Wai Tang and Sing Leung Lui and Siuwoo Cheung and S{\'e}amus Sreenan and Joseph A. Eustace and Donal O'Shea and Peter J. Lavin and Austin G. Stack and Yoram Yagil and Julio Wainstein and Hilla Knobler and Joseph Cohen and Irina Kenis and Deeb Daoud and Yosefa Bar-Dayan and Victor Frajewicki and Faiad Adawi and Loreto Gesualdo and Domenico Santoro and Francesco Marino and Andrea Galfr{\'e} and Chiara Carla Maria Brunati and Piero Ruggenenti and Giuseppe Rombol{\`a} and Giuseppe Pugliese and Maura Ravera and Fabio Malberti and Giuseppe Pontoriero and Teresa Rampino and Salvatore De Cosmo and Ciro Esposito and Felice Nappi and Cataldo Abaterusso and Giuseppe Conte and Vincenzo Panichi and Davide Lauro and Giovambattista Capasso and Domenico Russo and Jiichi Anzai and Motoji Naka and Kei Ato and Tetsuro Tsujimoto and Toshinori Nimura and Eitaro Nakashima and Tetsuro Takeda and Shinya Fujii and Kunihisa Kobayashi and Hideaki Iwaoka and Koji Nagayama and Hiroyuki Harada and Hajime Maeda and Rui Kishimoto and Tadashi Iitsuka and Naoki Itabashi and Ryuichi Furuya and Yoshitaka Maeda and Daishiro Yamada and Nobuhiro Sasaki and Hiromitsu Sasaki and Shin-ichiro Ueda and Naoki Kashihara and Shuichi Watanabe and Takehiro Nakamura and Hidetoshi Kanai and Yuichiro Makita and Keiko Ono and Noriyuki Iehara and Daisuke Goto and Keiichiro Kosuge and Ken-Ichi Tsuchida and Toshiaki Sato and Takashi Sekikawa and Hideki Okamoto and Tsuyoshi Tanaka and Naoko Ikeda and Takenobu Tadika and Koji Mukasa and Takeshi Osonoi and Fuminori Hirano and Motonobu Nishimura and Yuko Yambe and Yukio Tanaka and Makoto Ujihara and Takashi Sakai and Mitsuo Imura and Yutaka Umayahara and Shinya Makino and Jun Nakazawa and Yukinari Yamaguchi and Susumu Kashine and Hiroaki Miyaoka and Katsunori Suzuki and Toshihiko Inoue and Sou Nagai and Nobuyuki Sato and Masahiro Yamamoto and Noriyasu Taya and Akira Fujita and Akira Matsutani and Yugo Shibagaki and Yuichi Sato and Akira Yamauchi and Masahiro Tsutsui and Tamayo Ishiko and Shizuka Kaneko and Nobuyuki Azuma and Hirofumi Matsuda and Yasuhiro Hashiguchi and Yukiko Onishi and Mikiya Tokui and Munehide Matsuhisa and Arihiro Kiyosue and Junji Shinoda and Kazuo Ishikawa and Ghazali Ahmad and Shalini Vijayasingham and Nor Azizah Aziz and Zanariah Hussein and Yin Khet Fung and Wan Hasnul Halimi Wan Hassan and Hin Seng Wong and Bak Leong Goh and Norhaliza Mohd Ali and Nor Shaffinaz Yusuf Azmi Merican and Indralingam Vaithilingam and Nik Nur Fatnoon Nik Ahmad and Noor Lita binti Adam and Norlela Sukor and V Paranthaman P Vengadasalam and Khalid Abdul Kadir and Mafauzy Mohamed and Karina Renoirte Lopez and Aniceto Leguizamo-Dimas and Alfredo Chew Wong and Jos{\'e} Alejandro Chevaile-Ramos and Jos{\'e} Gerardo Gonz{\'a}lez Gonz{\'a}lez and Raul Rico Hernandez and Jos{\'e} Antonio Ni{\~n}o-Cruz and Leobardo Sauque Reyna and Guillermo Gonz{\'a}lez-G{\'a}lvez and Magdalena Madero Rovalo and Tomasso Bochicchio-Ricardelli and J. A Montemayor Aldrete and Jaime Carranza-Madrigal and Liffert Vogt and Peter Smak Gregoor and Jnm Barendregt and Pieter Teunis Luik and Ron T. Gansevoort and Gozewijn Dirk Laverman and Helen Pilmore and Helen Lunt and John Baker and Steven Miller and Kannaiyan Samuel Rabindranath and Luis Zapata-Rincon and Rolando Vargas-Gonzales and Jorge Calder{\'o}n Ticona and Augusto Dextre Espinoza and Jose Burga Nunez and Carlos Antonio Zea-Nu{\~n}ez and Benjamin Herrada Orue and Boris Medina-Santander and Cesar Delgado-Butron and Julio Farfan-Aspilcueta and Stanisław Mazur and Mirosław Nęcki and Michał Wruk and Katarzyna Klodawska and G Popenda and Ewa Skokowska and Małgorzata Arciszewska and Andrzej Więcek and Kazimierz Ciechanowski and Michał Nowicki and Rita Birne and Ant{\'o}nio Cabrita and Aura Ramos and Manuel Anibal A Ferreira and E. Fontanet and Altagracia Aurora Alcantara-Gonzalez and Angel Comulada-Rivera and E. G. Ramos and Jos{\'e} L. Cangiano and Luis Quesada-Suarez and Ricardo Ortiz and Jose B Vazquez-Tanus and Rafael Burgos-Calder{\'o}n and Carlos A. Rosado and Nicolae D Hancu and Ella Pintilei and Cristina Mistodie and Gabriel Bako and Lavinia Ionutiu and Ligia Petrica and Romulus Timar and Liliana- Ana Tuta and Livia Duma and Adriana-Carmen Tutescu and Svetlana Ivanova and A. M. Essaian and Konstantin Zrazhevskiy and Natalia Tomilina and Elena A. Smolyarchuk and Anatoly Kuzin and Olga E Lantseva and Irina A. Karpova and Minara S. Shamkhalova and Natalia Liberanskaya and Andrey Yavdosyuk and Yu. V. Shvarts and Tatiana P. Bardymova and Olga Blagoveshchenskaya and O. B. Solovev and Elena Rechkova and N. A. Pikalova and Maria G. Pavlova and Elena V. Kolmakova and Rustam Sayfutdinov and S. V. Villevalde and N. A. Koziolova and Vladimir A Martynenko and Vyacheslav Marasaev and A. N. Maksudova and Olga N. Sigitova and Viktor F. Mordovin and Vadim V. Klimontov and Yulia G. Samoylova and Tatiana L. Karonova and Lee Ying Yeoh and Boon Wee Teo and Marjorie Wai Yin Foo and Adrian Liew and Ivan Tk{\'a}{\vc} and Aniko Oroszova and Jozef Fekete and Jaroslav Rosenberger and Ida Obetkova and Alla Fulopova and Eva Koles{\'a}rov{\'a} and Katar{\'i}na Ra{\vs}lov{\'a} and Peter Smolko and Adri{\'a}n Ok{\vs}a and Larry A. Distiller and Julien Trokis and Luthando Adams and Hemant Makan and Padaruth Ramlachan and Essack Mitha and Kathleen Coetzee and Zelda Erika Punt and Qasim Ebrahim Bhorat and P Naiker and Graham Ellis and Louis T. van Zyl and Kwanbok Lee and Min Seon Kim and Soon Jib Yoo and Kun‐Ho Yoon and Yong-wook Cho and Tae Sun Park and Sang Yong Kim and Moon Gi Choi and Tae Keun Oh and Kang-Wook Lee and Ho Sang Shon and S H Suh and Byung-Joon Kim and Kim Doo-Man and Joo-Hark Yi and Sang Ah Lee and Ho Chan Cho and Sin Gon Kim and Dae Ryong Cha and Ji A. Seo and Kyung Mook Choi and Jeong Taek Woo and Kyu Jeung Ahn and Jae Hyuk Lee and In Joo Kim and Moon-Kyu Lee and Hak Chul Jang and Kyong Soo Park and Beom Seok Kim and Ji-Oh Mok and Mi-Sung Shin and Sun Ae Yoon and Il Seong Nam-Goong and Choon Hee Chung and Tae Yang Yu and Hyoung Woo Lee and Alfonso Soto Gonz{\'a}lez and Jaume Almirall and Jesus Egido and Francesca Calero Gonzalez and Gema Fern{\'a}ndez Fresnedo and Ildefonso Valera Cortes and Manuel Praga Terente and Isabel Garcia Mendez and Juan F. Navarro Gonz{\'a}lez and Jos{\'e} Herrero Calvo and Secundino Cigarr{\'a}n Guldris and Mario Prieto Velasco and Jos{\'e} Ignacio Minguela Pesquera and Antonio Gal{\'a}n and Julio Pascual and Maria Marques Vidas and Judith Martins Mu{\~n}oz and Jose Carlos Rodriguez-Perez and Cristina Castro-Alonso and Josep Bonet Sol and Daniel Ser{\'o}n and Elvira Fernandez Giraldez and Javier Arrieta Lezama and Nuria Montero and Julio Hern{\'a}ndez-Jaras and Rafael Santamar{\'i}a Olmo and Jos{\'e} Ram{\'o}n Molas Cot{\'e}n and Olof Hellberg and Bengt Fellstr{\o}m and Andreas H. Bock and Dee Pei and Ching-Ling Lin and Kai-Jen Tien and Ching-Chu Chen and Chien-Ning Huang and Ju-Ying Jiang and Du-An Wu and Chih-Hsun Chu and Shih-Ting Tseng and Jung-Fu Chen and Cho-Tsan Bau and Wayne H-H Sheu and Mai-Szu Wu and Ramazan Sarı and Siren Sezer and Alaattin Yildiz and Ilhan Satman and Betül Kalender and Borys Mankovskyy and Ivan M. Fushtey and Mykola Stanislavchuk and Mykola Kolenyk and I. O. Dudar and Viktoriia Zolotaikina and Orest Abrahamovych and Tetyana Kostynenko and Olena Petrosyan and Petro Kuskalo and Olga Galushchak and Oleg Legun and I. Topchii and Liliya Martynyuk and V. Stryzhak and Svitlana Panina and Sergii Tkach and Vadym Korpachev and Peter Maxwell and Luigi Gnudi and Sui Phin Kon and Hilary Tindall and Phillip A. Kalra and Patrick B. Mark and Dipesh C. Patel and Mohamed A. El-Shahawy and Liqun Bai and Romanita Nica and Yeong-Hau H Lien and Judson Menefee and Robert S. Busch and Alan Miller and Azazuddin Ahmed and Ahmed A. Arif and Joseph S. Lee and Sachin Desai and Shweta Bansal and Marie Bentsianov and Mario Belledonne and Charles S Jere and R. Gaona and Gregory Greenwood and Osvaldo A Brusco and Mark M. Boiskin and Diogo Belo and Raffi Minasian and Naveen K. Atray and Mary Kate Lawrence and John Vincent Taliercio and Pablo Pergola and David M. Scott and German Alvarez and Brad A Marder and Thomas Powell and Wa'el Bakdash and George Alin Stoica and Christopher McFadden and Marc S Rendell and Jonathan Wise and Audrey Jones and Michael R Jardula and Ivy-Joan Madu and Freemu Varghese and Brian Tulloch and Ziauddin Ahmed and Melanie Hames and Imran Nazeer and Newman Shahid and Rekha John and Manuel Montero and David Fitz-Patrick and L. Phillips and A. Guasch and Elena A Christofides and Aijaz A Gundroo and Mohammad I. Amin and Cynthia Bowman-Stroud and Michael Link and Laura C. Mulloy and Michael Nammour and Tarik Lalwani and Lenita Hanson and Adam Whaley-connell and Lee Herman and Rupi Chatha and Sayed Osama and Kenneth Liss and Zeid Kayali and Anuj Bhargava and Ezra Israel and Alfredo M. Peguero-Rivera and Michael Fang and Judith A. Slover and Elena Barengolts and Jose A. Flores and Rosemary Muoneke and Virginia J Savin and Stella Awua-Larbi and Andrew Levine and George Newman and Laden Golestaneh and Guillermo Bohm and Efrain Reisin and Lucita Cruz and Robert G. Weiss and Franklin J. Zieve and Edward J. Horwitz and Peale Chuang and James H. Mersey and John Manley and Ronald Graf and Fadi Bedros and Sudhir Joshi and Juan Pablo Frias and Ali Assefi and and Paul N. O'Shaughnessy and Roman R. Brantley and Todd Minga and David P. Tietjen and Samuel Kantor and Aamir Jamal and Ramon Guadiz and Kenneth S. Hershon and Peter Bressler and Nelson P. Kopyt and Harold Cathcart and Scott Bloom and Ronald R Reichel and Samer Nakhle and Emily J. Dulude and Joshua Tarkan and Penelope Baker and Steven Zeig and Jaynier Moya Hechevarria and Armando Ropero-Cartier and Gilda De la Calle and Ankur Doshi and Fadi Saba and Teresa Sligh and Sylvia Shaw and Jayant Kumar and Harold M. Szerlip and George P Bayliss and Alan S Perlman and L Sakhrani and Steven F. Gouge and Georges Argoud and Idalia Acosta and Jo-Anne Elder and Sucharit S. Joshi and John Sensenbrenner and S L Vicks and Roberto Mangoo-Karim and Claude M. Galphin and Carlos Leon-Forero and John Gilbert and Eric Brown and Adeel Ijaz and Salman Butt and Mariana S. Markell and Carlos Arauz-Pacheco and Lance A Sloan and O. Alvarado and Serge A. Jabbour and Eric Simon and Anjay Rastogi and Sam H James and Karen Hall and John . Melish and Bradley S. Dixon and Allen B Adolphe and Csaba Pal Kovesdy and Srinivasan Beddhu and Richard Solomon and R. Fernando and Ellis R. Levin and Charuhas V. Thakar and Brooks Robey and David Goldfarb and Linda P Fried and Geetha Maddukuri and Stephen Thomson and Andrew Annand and Saeed Kronfli and Paramjit Kalirao and Rebecca Schmidt and Neera K. Dahl and Samuel S. Blumenthal and Debra F. Weinstein and Ove Ostergaard and T Weinstein and Yasuhiro Ono and Murat Yalçın and Shahana Karim},
  journal={The Lancet},
  year={2019},
  volume={393},
  pages={1937-1947}
}

Figures and Tables from this paper

Individual Atrasentan Exposure is Associated With Long‐term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease
TLDR
The kidney protective effect was larger than the increase in heart failure supporting the atrasentan 0.75 mg/day dose in this population of type 2 diabetics with chronic kidney disease.
Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?
TLDR
Based on these results, canagliflozin will likely be approved for the indication of treating DKD in T2DM and the estimated glomerular filtration rate threshold for prescribing it will be lifted, whereas the future and place of atrasentan in the treatment of DKD remain unclear.
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
  • D. Wheeler, B. Stefánsson, H. Heerspink
  • Medicine
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2020
TLDR
The DAPA-CKD trial will examine the efficacy and safety of dapagliflozin in participants with CKD Stages 2–4 and increased albuminuria, with and without type 2 diabetes.
A narrative review of new treatment options for chronic kidney disease in type 2 diabetes.
TLDR
Renal outcome studies testing additional SGLT2 inhibitors and the GLP-1 receptor agonist semaglutide will report in the coming future potentially providing more and much needed options for treatment.
Treatments for Chronic Kidney Disease: A Systematic Literature Review of Randomized Controlled Trials
TLDR
Clinically objective outcomes of kidney failure and all-cause mortality (ACM) were reported in 32 and 64 trials, respectively and contemporary data suggest that augmenting RAAS inhibitors with new drug classes has the potential to improve clinical outcomes in a broad range of patients with CKD.
Sodium--glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: a new era has already begun.
TLDR
It is shown that canagliflozin substantially reduced the risk of doubling of SCr, end-stage kidney disease (ESKD), or death from renal or cardiovascular causes in 4401 patients with diabetic CKD compared with placebo, and relevant guidelines should accommodate their recommendations to implement treatment with SGLT-2 inhibitors.
Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence
TLDR
In the low baseline kidney-risk subgroups, SGLT2i initiation was generally associated with lower risk of the cardiovascular and cardiorenal outcomes, driven mainly by lower ACM incidence.
Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease
TLDR
Treatment with ERA induces long-term kidney protection in DKD, and phase 3 trials are underway to investigate ERA effects in patients with IgA nephropathy and FSGS.
Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial.
TLDR
Praliciguat treatment for 12 weeks did not significantly reduce albuminuria compared with placebo in the primary efficacy analysis, and the observed changes in urine albumin-creatinine ratio, BP, and metabolic variables may support further investigation of pralicigUat in diabetic kidney disease.
...
...

References

SHOWING 1-10 OF 25 REFERENCES
The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy.
TLDR
In conclusion, atrasentan reduced albuminuria and improved BP and lipid spectrum with manageable fluid overload-related adverse events in patients with type 2 diabetic nephropathy receiving RAS inhibitors.
Avosentan for overt diabetic nephropathy.
TLDR
In conclusion, avosentan reduces albuminuria when added to standard treatment in people with type 2 diabetes and overt nephropathy but induces significant fluid overload and congestive heart failure.
Combined angiotensin inhibition for the treatment of diabetic nephropathy.
TLDR
Combination therapy with an ACE inhibitor and an ARB was associated with an increased risk of adverse events among patients with diabetic nephropathy and safety outcomes included mortality, hyperkalemia, and acute kidney injury.
Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy.
TLDR
Atrasentan, at the doses tested, is generally safe and effective in reducing residual albuminuria and may ultimately improve renal outcomes in patients with type 2 diabetic nephropathy.
Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
TLDR
The addition of aliskiren to standard therapy with renin-angiotensin system blockade in patients with type 2 diabetes who are at high risk for cardiovascular and renal events is not supported by these data and may even be harmful.
The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy
TLDR
Post‐hoc analysis of urine samples collected during the RADAR study corroborate previous findings of mitochondrial dysfunction in patients with type 2 diabetes, nephropathy and eGFR and suggest that atrasentan may prevent the progression of mitochondria dysfunction common to this specific patient population.
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
TLDR
Albuminuria is the predominant renal risk marker in patients with type 2 diabetic nephropathy on conventional treatment; the higher the albuminuria, the greater the renal risk and the stronger the renal protection.
Avosentan reduces albumin excretion in diabetics with macroalbuminuria.
TLDR
The endothelin-A antagonist avosentan given in addition to standard ACEI/ARB treatment decreases UAER in patients with diabetic nephropathy and macroalbuminuria.
Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease.
TLDR
Findings suggest an important role for ET-1 in controlling systemic and renal haemodynamics in patients with CKD and the antihypertensive and potentially renoprotective actions of ET receptor antagonists shown in this study may prove useful in slowing the progression of CKD.
Unmet need in diabetic nephropathy: failed drugs or trials?
...
...